Data from Amylyx’s CENTAUR trial shows promise in slowing ALS progression

lesturner Foundation Blog, Home Page, Research & The Les Turner ALS Center

We are very pleased to share promising data published this week in the New England Journal of Medicine from the recent CENTAUR trial, conducted by Amylyx Pharmaceuticals, showing that AMX0035, the combination drug of sodium phenylbutyrate–taurursodiol, can slow functional decline …